PTIX Overview

Nasdaq Non-Compliance Notification: Protagenic Therapeutics (PTIX) received a notification from Nasdaq regarding its non-compliance with listing rules, specifically failing to meet the minimum stockholders' equity requirement of $2.5 million and not filing its September 30, 2025 Form 10-Q on time.

Delisting Determination: Due to recent compliance issues and a mandatory monitoring period, Nasdaq has determined to delist the company's securities, prompting PTIX to request a hearing to present its plan to rectify these deficiencies.

Quarterly Report Filing Delay: Protagenic Therapeutics announced a delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025, due to merger-related financial statement consolidation.

Anticipated Brief Delay: The company expects the delay to be short, but cannot guarantee a specific timeline for the filing.

Nasdaq Notice Received: Protagenic confirmed it received a notice from Nasdaq regarding its failure to file the Quarterly Report, although this does not affect the trading of its securities.

Current Stock Performance: Following the announcement, Protagenic's stock price increased by 1.41% after hours, reaching $4.3.

Stock Performance: Shares of Protagenic Therapeutics Inc (PTIX) surged over 100% after the announcement of a key clinical milestone in their Phase 1 trial for PT00114, a hormone therapy targeting stress and mood disorders.

Clinical Trial Update: The company successfully administered the first dose to all subjects in the multiple-dose portion of the trial and expects to complete dosing by the end of August, with topline safety data anticipated by the end of September.

Therapeutic Approach: PT00114 is based on Teneurin C-terminus Associated Peptide, a naturally occurring brain hormone aimed at regulating stress and emotional balance, potentially offering a treatment with fewer side effects.

Current Stock Price: As of Thursday afternoon, PTIX shares were trading at $4.02, reflecting a 76% increase, with a notable 52-week high of $15.54 and a low of $2.25.

U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling 0.62%, NASDAQ down 0.74%, and S&P 500 decreasing by 0.66% during Thursday's trading session.

Walmart's Mixed Earnings Report: Walmart shares dropped 4% after reporting second-quarter results that missed earnings expectations but exceeded sales forecasts, raising its annual outlook.

Notable Stock Movements: Aptorum Group's shares surged 155% following a health approval announcement, while ModivCare's stock plummeted 61% after filing for Chapter 11 bankruptcy.

Economic Indicators: Initial jobless claims rose to 235,000, existing home sales increased by 2%, and manufacturing PMI improved, while services PMI fell slightly in August.

U.S. Stock Market Performance: U.S. stocks opened lower with the Dow Jones dropping over 100 points, while the NASDAQ and S&P 500 also experienced declines.

Sector Movements: Health care shares increased by 0.2%, whereas consumer staples stocks fell by 1.2%.

Jobless Claims and Economic Indicators: Initial jobless claims rose to 235,000, exceeding market expectations, while existing home sales increased by 2% in July.

International Market Trends: European shares showed mixed results, and Asian markets closed variably, with Japan's Nikkei 225 and Hong Kong's Hang Seng both declining.

Patent Grant Announcement: Protagenic Therapeutics, Inc. has received a patent from the Japanese Patent Office for a modified stilbenoid aimed at treating epilepsy and seizures, which will provide exclusivity until March 31, 2041.

Market Insights: The Japanese pharmaceutical market is projected to grow from over $85 billion in 2025 to $93 billion by 2030, while the global epilepsy drug market is expected to increase from $11.29 billion in 2024 to around $18.74 billion by 2034.